Venture Fund Vi Lp Atlas Ve... Net Worth

The estimated Net Worth of Venture Fund Vi Lp Atlas Ve... is at least 295 百万$ dollars as of 2 August 2011. Venture Ve owns over 369,814 units of Horizon Therapeutics Plc stock worth over 294,625,930$ and over the last 13 years Venture sold HZNP stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Ve HZNP stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Horizon Therapeutics Plc stock since 2011, according to the Form 4 filled with the SEC. Most recently Venture bought 369,814 units of HZNP stock worth 3,328,326$ on 2 August 2011.

The largest trade Venture's ever made was buying 369,814 units of Horizon Therapeutics Plc stock on 2 August 2011 worth over 3,328,326$. On average, Venture trades about 369,814 units every 0 days since 2011. As of 2 August 2011 Venture still owns at least 2,533,327 units of Horizon Therapeutics Plc stock.

You can see the complete history of Venture Ve stock trades at the bottom of the page.

Insiders trading at Horizon Therapeutics Plc

Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over 454,905,275$ worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth 58,823,653$ . The most active insiders traders include Jeff Himawan、Woodlands Health Ventures F...、Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of 12,248,018$. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth 351,691$.

What does Horizon Therapeutics Plc do?

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Complete history of Venture Ve stock trades at Horizon Therapeutics Plc

Horizon Therapeutics Plc executives and stock owners

Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:

• Timothy Walbert,
  Chairman of the Board, President, Chief Executive Officer
• Timothy P. Walbert,
  Chairman, Pres & CEO
• Barry Moze,
  Executive Vice President, Chief Administrative Officer
• Paul Hoelscher,
  Chief Financial Officer, Executive Vice President
• Vikram Karnani,
  Executive Vice President, President - International
• Paul W. Hoelscher,
  Exec. VP & CFO
• Andy Pasternak,
  Exec. VP & Chief Strategy Officer
• Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
  Exec. VP & Chief Medical Officer
• Michael Grey,
  Lead Independent Director
• Jeffrey Himawan,
  Independent Director
• H. Thomas Watkins,
  Independent Director
• James Shannon,
  Independent Director
• William Daniel,
  Independent Director
• Pascale Witz,
  Independent Director
• Susan Mahony,
  Independent Director
• Irina Konstantinovsky,
  Chief Human Resource Officer, Executive Vice President
• Daniel Camardo,
  Executive Vice President, President - U.S.
• Jeffrey Kent,
  Senior Vice President, Head of Medical Affairs and Outcomes Research
• Andy Pasternak,
  Executive Vice President, Chief Business Officer
• Geoffrey Curtis,
  Executive Vice President - Corporate Affairs, Chief Communications Officer
• Tina Ventura,
  Senior Vice President, Investor Relations
• Michael DesJardin,
  Executive Vice President - Technical Operations and Corporate Quality
• Brian Beeler,
  Executive Vice President, General Counsel
• Aaron L. Cox,
  Exec. VP of Fin. & CFO
• Jane Gonnerman,
  Group VP of Corp. Devel., Chief of Staff & Office of the CEO
• Geoffrey M. Curtis,
  Exec. VP of Corp. Affairs & Chief Communications Officer
• Sean M. Clayton J.D.,
  Exec. VP & Gen. Counsel
• Timothy Ayers,
  Chief Compliance Officer & VP
• Dr. Karin Rosen M.D., Ph.D.,
  Exec. VP of R&D and Chief Scientific Officer
• Miles W. McHugh,
  Chief Accounting Officer & Sr. VP
• Robert Carey,
  EVP & Chief Business Officer
• Jeff Himawan,
  Director
• Gino Santini,
  Director
• Timothy J. Ackerman,
  SVP, Commercial Operations
• Miles W Mc Hugh,
  Sr VP & Princ. Acctg Officer
• George P Hampton,
  See remarks
• Virinder Nohria,
  Director
• Ronald Pauli,
  Director
• Vaere Robert J De,
  EVP & CFO
• Therapeutics Holdings Llc V...,
  10% owner
• Todd N Smith,
  SVP, Marketing & Alliance Mgmt
• David Happel,
  EVP, Commercial Dev & Strategy
• Eric Mosbrooker,
  SVP, Orphan Business Unit
• Shao Lee Lin,
  EVP, Head of R&D and CSO
• Jeff Kent,
  See remarks
• Jeffrey W Bird,
  Director
• Michael Adatto,
  Senior VP Sales & Managed Care
• Bio Ventures Ii Lp Quaker,
  10% owner
• Venture Fund Vi Lp Atlas Ve...,
  
• Peter Johann,
  Director
• Jean Francois Formela,
  Director
• Venture Fund Vi Lp Atlas Ve...,
  
• Woodlands Health Ventures F...,
  10% owner
• Louis C Bock,
  Director
• Hubert Birner,
  Director
• John B Thomas,
  EVP, Corporate Strategy and IR
• David George Kelly,
  EVP, Company Secretary
• John J Kody,
  EVP, Chief Commercial Officer
• Balaji Venkataraman,
  
• Aaron Cox,
  EVP, Chief Financial Officer
• Jeffrey W Sherman,
  EVP and Chief Medical Officer
• Karin Rosen,
  EVP, R&D & CSO
• Elizabeth H.Z. Thompson,
  EVP, Research & Development
• Sean M. Clayton,
  EVP, General Counsel
• Jacopo Leonardi,
  Pres., Global Commercial Ops
• Patrick Mc Ilvenny,
  Chief Accounting Officer